In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

IF 3.7 3区 医学 Q2 INFECTIOUS DISEASES
FATMA SENA TÜRKDOĞAN, Betigul Ongen
{"title":"In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae","authors":"FATMA SENA TÜRKDOĞAN,&nbsp;Betigul Ongen","doi":"10.1016/j.jgar.2024.10.097","DOIUrl":null,"url":null,"abstract":"<div><h3>AIM/BACKGROUND</h3><div>Carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains.</div></div><div><h3>METHODS</h3><div>Eighty-five CRKP clinical isolates were included in the study. The most common carbapenemase resistance genes (KPC, OXA-48, NDM, VIM, IMP) were investigated with the Xpert Carba-R Assay (Cepheid,USA). Cefiderocol susceptibility was detected by DD and broth microdilution (BMD) method using iron-depleted cation-adjusted Mueller-Hinton broth. Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam and eravacycline susceptibilities were detected by disk diffusion (DD) and gradient-test. Results were evaluated to FDA breakpoints for eravacycline and EUCAST breakpoints for others.</div></div><div><h3>RESULTS</h3><div>The most prevalent resistance gene was OXA-48 (55.2%), followed by NDM+OXA48 (32.9%), KPC (5.8%) and NDM (4.7%). Eravacycline was the most active agent with 97.6% susceptibility by DD and with MIC50/MIC90 results of 0.38/1 mg/L by gradient-test. Cefiderocol susceptibility was 43.5% by DD and 56.5% by BMD. Ceftazidime-avibactam susceptibility was 63.5% by both methods. Ceftazidime-avibactam inhibited all KPC and OXA-48 producers, while all NDM/NDM+OXA48 producers were resistant to ceftazidime-avibactam, except for one NDM+OXA-48 producer. Both meropenem-vaborbactam and imipenem-relebactam susceptibilities were 7% by DD, while 18.8% and 21.2% by gradient-test, respectively; these agents were resistant to all NDM/NDM+OXA48 producers except five isolates for meropenem-vaborbactam by gradient-test (Table).</div></div><div><h3>CONCLUSIONS</h3><div>Eravacycline and cefiderocol are promising in the treatment of CRKP, especially for MBL-producers. Ceftazidime-avibactam is a good treatment option for CRKP except for MBL-producers. Reasons behind the high cefiderocol MICs in resistant isolates need to be further investigates.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 31"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716524002741","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

AIM/BACKGROUND

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains.

METHODS

Eighty-five CRKP clinical isolates were included in the study. The most common carbapenemase resistance genes (KPC, OXA-48, NDM, VIM, IMP) were investigated with the Xpert Carba-R Assay (Cepheid,USA). Cefiderocol susceptibility was detected by DD and broth microdilution (BMD) method using iron-depleted cation-adjusted Mueller-Hinton broth. Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam and eravacycline susceptibilities were detected by disk diffusion (DD) and gradient-test. Results were evaluated to FDA breakpoints for eravacycline and EUCAST breakpoints for others.

RESULTS

The most prevalent resistance gene was OXA-48 (55.2%), followed by NDM+OXA48 (32.9%), KPC (5.8%) and NDM (4.7%). Eravacycline was the most active agent with 97.6% susceptibility by DD and with MIC50/MIC90 results of 0.38/1 mg/L by gradient-test. Cefiderocol susceptibility was 43.5% by DD and 56.5% by BMD. Ceftazidime-avibactam susceptibility was 63.5% by both methods. Ceftazidime-avibactam inhibited all KPC and OXA-48 producers, while all NDM/NDM+OXA48 producers were resistant to ceftazidime-avibactam, except for one NDM+OXA-48 producer. Both meropenem-vaborbactam and imipenem-relebactam susceptibilities were 7% by DD, while 18.8% and 21.2% by gradient-test, respectively; these agents were resistant to all NDM/NDM+OXA48 producers except five isolates for meropenem-vaborbactam by gradient-test (Table).

CONCLUSIONS

Eravacycline and cefiderocol are promising in the treatment of CRKP, especially for MBL-producers. Ceftazidime-avibactam is a good treatment option for CRKP except for MBL-producers. Reasons behind the high cefiderocol MICs in resistant isolates need to be further investigates.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of global antimicrobial resistance
Journal of global antimicrobial resistance INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
CiteScore
8.70
自引率
2.20%
发文量
285
审稿时长
34 weeks
期刊介绍: The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes. JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR). Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信